Current open trials

Biogen is conducting numerous clinical trials in neurologic, hematologic, and immunologic diseases to evaluate the efficacy and safety of potential therapies. Learn more about our currently enrolling trials by disease area here.

Alzheimer's Disease

Our phase 3 trials for aducanumab are enrolling people in the early stages of Alzheimer’s disease

Trial information 
Multiple Sclerosis

We are conducting a variety of studies to better understand our marketed and investigational MS treatments

Trial information 
Spinal Muscular Atrophy

With our collaborator Isis Pharmaceuticals, we are conducting late-stage clinical trials for this genetic disease

Trial information

We conduct clinical trials both to determine the safety and efficacy of investigational therapies and to better understand how to use our approved products.  This includes exploring new ways of dosing or administering our medicines, or even testing them in a different disease.

Getting a new therapy to market can take 15 years or more, and only one out of approximately 10,000 identified potential therapies will ultimately be approved. For patients, this process can seem slow, but it is critical for ensuring that the therapy is safe and effective. The data gathered during our trials is also invaluable to the global healthcare community since it sheds new light on specific diseases and on human biology in general.

The approval of a new therapy requires years of research and development to ensure that a product is safe and effective. After a potential therapy has been thoroughly tested in a lab setting and deemed promising, it must pass through a strictly regulated approval process. This process spans three phases of clinical trials, or research studies, each with a different purpose and involving an increasing number of people.

Clinical trials follow strict, scientific standards that protect patients and help produce reliable trial results. Every clinical trial has a protocol, or study plan, that describes what will be done during the trial, how the trial will be conducted, and why each part of the trial is necessary.

BEGINNING THE PROCESS
Before a clinical trial on a potential therapy can start, Biogen submits an Investigational New Drug (IND) in the United States, or a Clinical Trial Application (CTA) as it’s called outside the U.S. to the local regulatory agency. We work with regulatory agencies around the world, including the Food and Drug Administration (FDA) in the U.S. and the European Medicines Agency (EMA) in Europe. The application describes the results of preclinical testing and clearly outlines the plan for conducting clinical trials.

PHASE I
Trials in Phase One emphasize safety and are usually conducted with healthy volunteers. The goal is to learn how the potential therapy is metabolized and to uncover its most frequent and serious side effects.

PHASE II
Trials in Phase Two gather preliminary data on how the potential therapy works for people with the target disease or condition. Some trials compare results for two different test groups: participants receiving the potential therapy and participants receiving a different treatment – either another drug or placebo. Researchers continue to pay close attention to safety and possible side effects.

PHASE III
In this final clinical phase, investigators gather more comprehensive information about a potential therapy’s safety and effectiveness. Trials might examine different patient populations, compare different dosage amounts of the potential therapy, or combine it with other treatments.

Once Phase Three is completed, the potential therapy can be filed with regulatory authorities like the FDA or EMA, which can then approve as a therapy for public use.

POST-MARKET RESEARCH
After a therapy has been approved, regulatory agencies often require additional studies. These post-marketing studies may evaluate the therapy on new patient populations, monitor the long-term impact or compare the therapy with other therapies.